Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04350593 · ClinicalTrials.gov registry record · Phase 3
Dapagliflozin in Respiratory Failure in Patients With COVID-19
A Phase 3 study, sponsored by Saint Luke's Health System.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,250
- Enrollment target
NCT04350593 is a Phase 3 study that has completed, run by Saint Luke's Health System. The registered enrollment target is 1,250 participants.
The verdict
NCT04350593, a Phase 3 study, has completed, sponsored by Saint Luke's Health System.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,250 participants
- Enrollment target
Study Summary
This is an international, multicenter, parallel-group, randomized, double-blind, placebo controlled, study in hospitalized adult patients with coronavirus disease 2019 (COVID-19) in the United States, Brazil, Mexico, Argentina, India, Canada, and United Kingdom. The study is evaluating the effect of dapagliflozin 10 milligrams versus placebo, given once daily for 30 days in addition to background local standard of care therapy, on reducing complications and all-cause mortality, or improving clinical recovery.
Interventions
- DRUG Placebo
- DRUG Dapagliflozin 10 milligram (mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 2020-04-22 |
| Est. Completion | 2021-06-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04350593
The ClinicalTrials.gov registry entry for NCT04350593 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Saint Luke's Health System, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04350593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04350593 about?
NCT04350593 is a clinical study titled "Dapagliflozin in Respiratory Failure in Patients With COVID-19". This is an international, multicenter, parallel-group, randomized, double-blind, placebo controlled, study in hospitalized adult patients with coronavirus disease 2019 (COVID-19) in the United States, Brazil, Mexico, Argentina, India, Canada, and United Kingdom. The study is evaluating the effect of...
What is the current status of trial NCT04350593?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,250 participants. The study started on 2020-04-22. Estimated completion is 2021-06-11.
What interventions are being tested in trial NCT04350593?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin 10 milligram (mg) (DRUG).
Who is sponsoring clinical trial NCT04350593?
This trial is sponsored by Saint Luke's Health System, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.